Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13604098 | 1.00 | SRD5A1 (0.72) | SRD5A1SRD5A2 | |
| SCHEMBL9571051 | 1.00 | SRD5A1 (0.72) | SRD5A1SRD5A2 | |
| SCHEMBL8021083 | 0.90 | SRD5A1 (0.72) | SRD5A1SRD5A2 | |
| SCHEMBL4187755 | 0.90 | SRD5A1 (0.72) | SRD5A1SRD5A2 | |
| SCHEMBL9349878 | 0.90 | SRD5A1 (0.72) | SRD5A1SRD5A2 | |
| SCHEMBL4187752 | 0.90 | SRD5A1 (0.72) | SRD5A1SRD5A2 | |
| SCHEMBL13604091 | 0.90 | SRD5A1 (0.72) | SRD5A1SRD5A2 | |
| SCHEMBL8724807 | 0.89 | SRD5A1 (0.71) | SRD5A1SRD5A2 | |
| SCHEMBL9348446 | 0.89 | SRD5A1 (0.71) | SRD5A1SRD5A2 | |
| SCHEMBL9278658 | 0.89 | SRD5A1 (0.68) | SRD5A1SRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4377584-A | 4-Aza-17β-substituted-5α-androstan-3-one-reductase inhibitors | MERCK & CO., INC. (US) | 1983-03-22 | — | — | US | claimed |
| US-8012958-B2 | Modulate gene expression of gamma-aminobutyric acid receptors ; antidepressants; psychological disorders; obsessive compulsive disorders ; eating disorders | Hythlam, Inc. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20080280885-A1 | Methods for Treating Anxiety Related Disorders | HYTHIAM, INC. (US) | 2008-11-13 | — | — | US | disclosed |
| US-20080255097-A1 | Methods for the Treatment of Substance Abuse and Dependence | HYTHIAM, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080207601-A1 | Methods of and Compositions For the Prevention of Anxiety, Substance Abuse, and Dependence | HYTHIAM , INC. (US) | 2008-08-28 | — | — | US | disclosed |
| EP-1901727-A2 | METHODS FOR THE TREATMENT OF SUBSTANCE ABUSE AND DEPENDENCE | Hythiam, Inc. (US) | 2008-03-26 | — | — | EP | disclosed |
| EP-1868593-A2 | IMPROVED METHODS OF AND COMPOSITIONS FOR THE PREVENTION OF ANXIETY, SUBSTANCE ABUSE, AND DEPENDENCE | Hythiam, Inc. (US) | 2007-12-26 | — | — | EP | disclosed |
| EP-1868432-A2 | METHODS FOR TREATING ANXIETY RELATED DISORDERS | Hythiam, Inc. (US) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006110580-A2 | METHODS FOR TREATING ANXIETY RELATED DISORDERS | HYTHIAM, INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006110557-A2 | METHODS FOR THE TREATMENT OF SUBSTANCE ABUSE AND DEPENDENCE | HYTHIAM, INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006110642-A2 | IMPROVED METHODS OF AND COMPOSITIONS FOR THE PREVENTION OF ANXIETY, SUBSTANCE ABUSE, AND DEPENDENCE | HYTHIAM, INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| US-4377584-A | 4-Aza-17β-substituted-5α-androstan-3-one-reductase inhibitors | MERCK & CO., INC. (US) | 1983-03-22 | — | — | US | disclosed |